Brief: Gri Bio Announces Additional Positive Data From Phase 2A Study In Idiopathic Pulmonary Fibrosis
08/01/2026 13:09
Jan 8 (Reuters) - GRI Bio Inc GRI.O: GRI BIO ANNOUNCES ADDITIONAL POSITIVE DATA FROM PHASE 2A STUDY IN IDIOPATHIC PULMONARY FIBROSIS, STRENGTHENING CLINICAL PROOF-OF-CONCEPT FOR GRI-0621 GRI BIO INC: GRI-0621 CONTINUES TO DEMONSTRATE A COMPELLING PROFILE, COMBINING FAVORABLE SAFETY AND TOLERABILITY Source text: ID:nGNX5CJhdQ Further company coverage: GRI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on GRI Bio
See all newsGRI Bio Inc reports results for the quarter ended June 30 - Earnings Summary
GRI Bio Inc expected to post a loss of $1.19 a share - Earnings Preview
Brief: Gri Bio Secures FDA Orphan Drug Designation For Gri-0621 (Tazarotene) In Idiopathic Pulmonary Fibrosis
GRI Bio Q1 net loss narrows on lower R&D expenses
GRI Bio raises $14.5 mln to fund operations into Q1 2027